Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Sep 01, 2005 (Vol. 25, No. 15)

Cell Signaling Technology

URL:www.cellsignal.com
  • Pathways
  • Nothing significant
Say you’re a biotech company and you want scientists to come visit your site so they can see your products. What’s the best way to get them there? To no one’s surprise, save a surprisingly large number of biotech executives, you’ve got to put something on the site besides product information. The number of requests I get to review commercial sites that are nothing more than ads for products is depressing. Where did these people learn about marketing? The advertising model of television says people will tolerate commercials if there is a good show that goes with it. The designer of Cell Signaling Technology’s page has learned the importance of using content to get site visitors. The bait here is an extensive set of signaling pathways that users can view and then click to download products, as available. The pathways are attractively designed and the commercial aims are not in anyone’s face. Very well done.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »